AR and neoplasm: Given the impact of this standard-of-care combination, we next evaluated the combination of Ad-AR-V7 with anti-PD1 checkpoint inhibition to enable CD8+ T cells in our P3CA-AR-V7 tumor model, as we have observed in other studies [15].